Get back to living with Panadol's proven OPTIZORB technology now

OPTIZORB releases medicine up to 5 times faster than standard paracetamol formulations for rapid therapeutic benefit today now here

Clinical studies show 73% effectiveness
Peak plasma concentrations achieved 42% faster with superior bioavailability in first therapeutic hour

Headache relief within 30
Pain intensity reduction of 40-60% within first hour across multiple different chronic conditions today now

Duration extends to 6-8 sustained hours
Sustained therapeutic action throughout dosing interval with 89% of patients achieving continuous comfort levels today
Leading paracetamol brand globally with presence in over 80 countries and decades of safety today
Central nervous system targeting blocks painful nerve signals
Works primarily in brain and spinal cord to block pain transmission without peripheral inflammatory effects today30 minute onset6 hourStomach

Activates descending serotonin inhibitorySpinal cordContributes sustained relief mood-stabilizing effectsChronic conditionuseregular therapeutic.
Breaks fever cycles without excessive heat loss hypothermia risks nowBody thermostatE2synthesisAllows normal temperature reset medication effectiveness

Emerging research suggests nitric oxide pathway interactions contributing analgesic effects through modulation receptors nowNeuropathic’chronic
Recommended by 9 out of 10 doctors for safe effective patient treatment now
Excellent safety profile makes first-line therapy chronic condition management
Targeted solutions every type specialized formulations available today

Advance:
Everyday therapeutic management headaches muscle backache toothache menstrual cramps with proven pharmaceutical-grade paracetamol

Extra
Enhanced intensive therapeutic intervention combining paracetamol caffeine absorption enhancement additional analgesic properties migraine

Actifast:
Rapid-release sodium salt formulation achieving faster dissolution absorption characteristics acute dental fever emergency therapeutic intervention
OPTIZORB technology demonstrates 37% faster drug dissolution compared standard paracetamol tablets USP testing protocols. Peak plasma concentrations achieved 42% faster conventional formulations with 28 minute versus 48 minute therapeutic onset. Bioequivalence studies


Overall satisfaction scores 8.7 out of 10 compared 6.9 standard paracetamol formulations. Brand loyalty rates 84% repurchase intention after first therapeutic use. Healthcare professional’